The Infectious Diseases Society of America's (IDSA) 2014 guidelines for the diagnosis and management of skin and soft-tissue infections recommend that mild to moderate nonpurulent ABSSSI be treated with a beta-lactam or clindamycin as presumptive coverage for streptococci.